Objectives. Polyarteritis nodosa (PAN) is a term that has been used to describe a wide variety of vasculitic conditions. In 1994, the Chapel Hill Consensus Conference on the nomenclature of systemic vasculitides proposed that the name classical PAN should be restricted to diseases where there is arteritis in small and medium-sized arteries without the involvement of smaller vessels. Our aim was to describe the symptoms and course of disease in PAN when the microscopic forms are excluded. Methods. All patients with a diagnosis of PAN treated in our departments during the period 1990-2002 were eligible for this study. The diagnosis had to be confirmed by biopsy, angiography or electromyography. Results. Ten patients were eligible for the study. The median age was 46 yrs. Renal involvement was seen in 70% at diagnosis. After 5 yrs, 57% had experienced a relapse, which is equivalent to the relapse rate seen in microscopic polyangiitis. Organ damage was assessed by the Vasculitis Damage Index (VDI) and after 5 yrs cardiovascular and neuropsychiatric damage dominated, followed by renal damage. During the follow-up, two patients developed end-stage renal disease. The annual incidence of PAN in our local catchment area was estimated to 1.6 per million and year. Conclusions. When applying the Chapel Hill nomenclature, PAN is a rare but severe disease with a high incidence of renal involvement and frequent relapses.
Introduction
In 1866, Kussmaul and Maier [1] described a patient dying from a previously unknown disease for which they gave the descriptive name of periarteritis nodosa. This and the other similar designations such as polyarteritis nodosa (PAN) were subsequently used as diagnostic terms for an increasing number of different vasculitic conditions. The separation into specific subgroups of vasculitides was started by Wegener [2] in 1939. In 1948, a microscopic form of polyarteritis was described by Davson et al. [3] who suggested that segmental necrotizing glomerulonephritis was a feature of this form of the disease. In 1952, Zeek [4] pointed out that the term PAN had gradually encompassed a wide variety of vascular conditions and proposed a classification for necrotizing angiitides in which PAN was separated from other forms. Although many authors adopted this terminology, most continued to include glomerulonephritis as a manifestation of PAN. Moreover, the American College of Rheumatology (ACR) classification criteria since 1990 [5] do not distinguish between classical PAN and microscopic polyangiitis (MPA).
In 1970, Tre´po and Thivolet [6] described hepatitis-induced PAN. This secondary form of vasculitis was more common in Western Europe in the 1970s due to hepatitis B virus (HBV) infection caused by contaminated blood transfusions. Today, hepatitis-associated PAN is treated with antiviral drugs and the clinical course after such treatment is usually benign.
The relationship between anti-neutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis was first described by van der Woude [7] in 1985. In 1994, the Chapel Hill Consensus Conference (CHCC) on the nomenclature of systemic vasculitides [8] proposed that the name classical PAN should be restricted to disease where there is arteritis in small and medium-sized arteries without the involvement of smaller vessels. According to the CHCC nomenclature, PAN is a systemic necrotizing vasculitic disease of unknown aetiology characterized by inflammation and necrosis of small and medium-sized arteries.
After the publication of the CHCC document many patient series have been presented describing the clinical features of MPA [9] [10] [11] [12] . However, with the exception of a small study by Kirkland et al. [13] , we have found no PAN study that strictly comply with the CHCC nomenclature; consequently, the clinical features for PAN are not completely known when applying the new definitions. The aim of the present study was to describe the symptoms, signs and clinical course of a cohort of patients who fulfil the CHCC definition for PAN.
Patients and methods

Population details
The study was performed at the Departments of Nephrology and Rheumatology at the Lund University Hospital, which is a tertiary hospital for a region in South Sweden with a population of 1 575 000, and also a local hospital for a district with 282 900 inhabitants. The largest community in this district is the city of Lund with around 100 000 inhabitants. There are several mediumsized communities where a large percentage of the working population commutes to and from Lund and Malmo¨(the third largest city in Sweden). There is a substantial rural population but 81% live in communities with more than 1000 inhabitants according to Statistics Sweden (www.scb.se). Females make up 50.4% of the population. The age distribution is as follows: 0-14 yrs (18.8%); 15-34 yrs (27.1%); 35-54 yrs (27.5%); 55-74 yrs (19.1%) and 75 yrs and above (7.5%). Twelve percent of the inhabitants are born outside Sweden, most of them being immigrants from other Nordic countries or Southern Europe.
The distances in this area are short; no community is more than 40 km from Lund, and the distance between Lund and Malmo¨is only 17 km. Beside the University Hospital in Lund there is one smaller hospital in the city of Landskrona, without any specialists in rheumatology and nephrology.
Patients
All the patients with a diagnosis of PAN treated in our departments, including those living outside our local catchment area, during the period January 1990-December 2002 were eligible for this study. Every person in Sweden has a unique personal identification number and all the patients are registered in the patient administrative registry with ICD codes at every visit and admission to the hospital. The patients were identified by means of the patient administrative registry, searched for PAN and related diagnoses, using ICD 9 codes 446 and 447 for the period 1990-97, and the ICD 10 codes M30 and M31 from 1998. For the period 1997-2002, the search was extended to include six other departments in Lund and the selected departments at the four neighbouring hospitals (including Malmo¨University Hospital). In addition, the registries at the Department of Pathology were searched using the term 'vasculitis'. This extended search was part of an ongoing larger epidemiological study.
Patients were included in the study if they had a disease compatible with systemic vasculitis with histological evidence of vasculitis affecting small or medium-sized arteries and/or with angiographic features of multiple micro-aneurysms and multiple stenoses and/or with an electromyography (EMG) typical for mononeuritis multiplex. A documented ANCA-test, determined by indirect immunofluorescence (IIF) assay and/or enzyme-linked immunosorbent assay (ELISA) to proteinase-3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, either at diagnosis or relapse was also required. ANCA is strongly associated with small vessel vasculitis and is usually absent in reports of PAN. Although a positive ANCA does not exclude a diagnosis of PAN, according to the CHCC definitions we consider ANCA to be a marker of small vessel disease and, therefore, to exclude a diagnosis of PAN. Patients were excluded from the study if there were histological or clinical signs of small vessel vasculitis such as pulmonary capillaritis, with lung bleeding or glomerulonephritis, as confirmed by histology or indicated by cellular casts in the urinary sediment or positive PR3-ANCA or MPO-ANCA. Patients were not included if the symptoms and signs could be attributed to another disease, e.g. cancer, infection, other forms of vasculitis including hepatitis-associated vasculitis. Fulfillment of the ACR criteria established by ACR [5] was not considered mandatory for this study.
Data collected at the time of diagnosis
The patient case records were reviewed in detail. From the time of diagnosis the following data were retrieved: age, gender, the first clinical signs attributable to vasculitis, clinical signs at the time of diagnosis, the time period to diagnosis (defined as the time from the first signs attributable to vasculitis until the date vasculitis was diagnosed by angiography or biopsy), serum creatinine, weight, length (for children), urine albumin, urinary sediment findings and blood pressure at the time of diagnosis, serology for hepatitis B and C, disease activity at diagnosis as assessed by the Birmingham Vasculitis Activity Score (BVAS) and the five-factor score (FFS). The BVAS was created by a group in Birmingham in 1994 [14] to measure the disease activity in patients with a variety of systemic vasculitides. It scores abnormality ascribable to the presence of active vasculitis. The maximum possible score is 63. The FFS was created by Guillevin et al. [15] in 1996 by evaluating different parameters for predicting the outcome in patients with PAN. The five factors found to predict excess mortality in that study were renal insufficiency (serum creatinine 140 mol/l), proteinuria (>1 g/day), severe gastrointestinal involvement, cardiomyopathy and CNS involvement. Glomerular filtration rate (GFR) was calculated from the Cockcroft-Gault equation [16] in adult patients and from the Schwartz equations [17, 18] in children and adolescents.
Data collected during follow-up
The patients were followed until December 2003. During follow-up, the following data were recorded: treatment, time and cause of death, time of end-stage renal disease (ESRD), time of and symptoms at relapse and Vasculitis Damage Index (VDI) at 1 and 5 yrs. VDI was created in 1997 [19] to aid in the separation of damage from disease activity in systemic vasculitis. The VDI scores damage due to non-healing scars from any cause that has occurred since the onset of vasculitis. It is a cumulative assessment of organ dysfunction, damage or scarring and either remains stable or increases with time. It includes assessment of ten organ systems: musculoskeletal; skin; ear, nose and throat; pulmonary; cardiovascular; renal; gastrointestinal; peripheral vascular; ocular and neuropsychiatric; and also other damages like premature gonadal failure, marrow failure, diabetes mellitus, chronic chemical cystitis, malignancy and other features considered to be an important scar or consequence that has arisen since the onset of disease. Sixty-four items of damage are scored.
Relapse was defined as the occurrence of one of the following: (i) general symptoms, i.e. malaise, fever, weight loss, myalgia, arthralgia, in conjunction with a rise in CRP, when infection and other causes were ruled out; (ii) gastrointestinal or renal infarction or bleeding from aneurysms, as seen at surgery or strongly suspected by angiography; (iii) new mononeuritis multiplex; (iv) a rapid rise in serum creatinine levels and blood pressure; (v) testicular pain; (vi) skin vasculitis; and (vii) uveitis, when (i-vii) were considered to be due to vasculitis. For the comparison of relapses, 62 consecutive patients with MPA with biopsy-proven renal involvement from a previous study [20] were analysed regarding time until the first relapse.
Ethics
The study was approved by the local Ethical Committee at the Faculty of Medicine, Lund University.
Statistics
The comparisons between BVAS and VDI were carried out with the Spearman rank correlation test using GraphPad InStat version 3.
Results
Fifteen patients with a probable diagnosis of PAN were identified in this study. Five patients all diagnosed before 1983, were excluded because possible co-existence of small vessel vasculitis could not be ruled out. Median age at diagnosis for the excluded patients was 53 yrs (range 28-61). Renal involvement was seen in three of these patients and three had skin involvement at diagnosis. Two patients had nerve involvement and lung involvement was seen in two. Median follow-up time was 14 yrs (range 14-45). One patient had a relapse 10 yrs after the start of treatment.
Ten patients, five males and five females, fulfilled all the criteria listed above and were included in the study. Four patients were diagnosed by biopsy (testis, muscle, epididymis and skin), four by angiography and one was positive in both procedures. One patient had typical mononeuritis multiplex confirmed by EMG and nerve biopsy was compatible, but not diagnostic for vasculitis in medium-sized vessels. All diagnostic biopsies showed inflammation and necrosis in small or medium-sized arteries, but not in arterioles and other small-sized vessels. No patient presented multiple positive biopsies. All ten patients fulfilled at least three ACR criteria, median 3 (range 3-5). All patients exhibited multiple negative ANCA tests. One patient was diagnosed at the Paediatric Clinic before ANCA testing was available. He was ANCAnegative at relapse and in all subsequent ANCA tests, IIF as well as ELISA. All the other patients were ANCA-tested at the time of diagnosis. Only one patient was found to have had hepatitis (B and C) that could have contributed to the development of PAN. He was tested positive for HBV 13 yrs before he showed any symptoms attributable to vasculitis. At the time of diagnosis he was positive for HBV antibodies, but negative for HBV antigen. We do not consider PAN in this patient to be HBV induced. At the time when HBV was diagnosed, hepatitis C virus (HCV) was not known and hence he was not tested for this. At the time of diagnosis of PAN he also had antibodies to HCV.
During the 13 yrs period, six new cases were diagnosed among patients living in our local catchment area of 282 900 inhabitants. This gives an annual incidence of 1.6 per million. One patient was diagnosed at the Paediatric Clinic before the 13 yrs period and three were referred from areas outside the local catchment area. All excluded patients were diagnosed before this 13 yrs period and would not have influenced the incidence estimate if included. The extended search in registries from other departments and neighbouring hospitals did only yield one patient with possible PAN living in the local study area. That patient was diagnosed in 1983 and ended up in the group excluded because of insufficient data (see aforesaid). Due to the low yield of this search, we did not attempt to extend it further back in time.
Clinical manifestations at diagnosis
The parameters assessed at the time of diagnosis are detailed in Table 1 . The median age was 46 yrs (range 8-78), and the first symptoms attributable to vasculitis were dominated by myalgia, malaise, headache and fever. The time from the first symptoms attributable to vasculitis until diagnosis (diagnosis delay) varied from 2 weeks to 39 months (median five months). All the patients had systemic symptoms. Renal involvement (proteinuria, haematuria and/or renal microaneurysms in angiography) was seen in seven (70%) patients, but only two had elevated serum creatinine levels at the time of diagnosis. Five patients had renal aneurysms on angiography, and three of these also had microscopic haematuria and/or proteinuria even though renal infarcts were not noted. The other two patients with renal involvement had microscopic haematuria or low grade proteinuria. No renal biopsies were performed at the time of diagnosis since none of the patients exhibited red cell casts, dysmorphic red cells or other cell casts indicative of glomerulonephritis. One patient underwent renal biopsy during a flare with a rise in serum creatinine, but there were no signs of glomerulonephritis. The median serum creatinine at diagnosis was 65 mol/l (range 45-292). Four patients were hypertensive, including three with malignant hypertension. The vasculitic activity at diagnosis was scored according to BVAS as shown in Fig. 1 and Table 1 . The median BVAS score was 17 (range 5-33). Symptoms at diagnosis were dominated by renal and nervous system involvement. The FFS for each patient is shown in Table 1 . The FFS varied from 0 to 3 (median 0). Patients with the highest FFS tended to have short diagnostic delay.
Follow-up
The patients were followed for 0.5-19.8 yrs (median 6.0 yrs). No patient was lost to follow-up. The parameters assessed during follow-up are detailed in Table 2 . All patients received induction therapy with a combination of steroids and cyclophosphamide (8 patients) or azathioprine (2 patients). In addition to steroids and cyclophosphamide, one patient underwent treatment with plasma exchange. An elderly woman died 5 months after diagnosis without achieving remission. She had chronic heart failure, a progressive disease and repeated infections during immunosuppressive treatment. Autopsy was not performed. In this case, BVAS was 22 and FFS 0 at diagnosis. All the other patients achieved remission within 6 months. Seven patients had altogether 11 relapses. Eight of the relapses were seen in the same organs that were affected at the time of diagnosis. In addition to this, one patient had several episodes of pancreatitis that were considered to be due to previous damage and scarring. These episodes were not classified as relapses. The median time from diagnosis to first relapse was 3.2 yrs (range 0.7-6.8). Within 5 yrs 57% of the patients had experienced a relapse. The relapse tendency for these PAN patients does not seem to differ from a cohort of 62 MPA patients previously described [20] , as shown in Fig. 2 .
During follow-up, organ damage attributable to vasculitis was assessed by the VDI at 1 and 5 yrs after diagnosis. The scores are detailed in Table 3 . After 1 yr, cardiovascular and neuropsychiatric damage dominated. Only one of the nine patients that survived the first year had enough renal damage to get a renal VDI score. After 5 yrs of follow-up, again neuropsychiatric and cardiovascular damage dominated, followed by renal damage. Two patients progressed to ESRD and started haemodialysis 6.5 and 8 yrs after diagnosis. Both had malignant hypertension at the time of diagnosis and both had a relapse with rise in creatinine and hypertension.
Even though the study was small, according to the Spearman rank correlations test there was a significant correlation between high BVAS at diagnosis and high VDI at follow-up, both at 1 yr (P ¼ 0.0029) (n ¼ 9) and 5 yrs (P ¼ 0.0072) (n ¼ 7).
Discussion
In the present study, we report on ten patients diagnosed with PAN, who all lack direct evidence of small vessel disease such as glomerulonephritis or capillaritis and indirect evidence such as ANCA. Since the publication of the CHCC nomenclature, many studies have been published describing the microscopic form of polyarteritis [9] [10] [11] [12] . To the best of our knowledge there is only one study before [13] the present study that describes classical PAN strictly adhering to this nomenclature. As in other studies using less restrictive inclusion criteria PAN typically developed subacutely, with the onset of constitutional symptoms over weeks to months. Only few had an acute onset, and in those cases the symptoms were severe with malignant hypertension, renal insufficiency and gastrointestinal involvement.
Even though we had excluded patients with glomerulonephritis, organ involvement at diagnosis was dominated by renal involvement. In our study, seven patients (70%) had signs of renal involvement at the time of diagnosis, which is more than what the other authors have found. Fortin et al. [21] found 44% renal involvement and Agard et al. [22] found 22% in their studies. Two patients (20%) in our study developed ESRD during follow-up and both had relapses with renal involvement. This shows that patients with PAN must be followed closely to avoid deterioration of renal function.
The ACR document has positivity for HBV as a classification criterion for PAN. Recent reports show that HBV-associated arteritis responds to anti-viral therapy and that relapse after such treatment seems to be rare. If the clinical course, outcome and response to treatment differ between PAN with and without HBV association, we consider it unwise to lump these two conditions into one disease entity. For one patient in our series, we had difficulty in interpreting the role of viral infection. In this case, HBV infection could be tracked 13 yrs back and at the time of diagnosis he was positive for HBV antibodies but negative for HBV antigen. Guillevin et al. [23] have described patients with HBV-induced PAN as an acute disease, occurring shortly after infection. In their study, the median time from HBV infection to development of PAN was 2 months. We do not consider PAN in our patient to be HBV-induced, but we cannot completely rule out this possibility. Peripheral nerve involvement is a feature that may be more prevalent in HBV-associated PAN. We found this complication in five of our patients (50%). This is less than what the others have reported [22, 24] . In one report on patients with HBV-related PAN, the incidence of peripheral neuropathy was 83% [23] .
Relapse is another feature that most probably is influenced by the percentage of HBV-associated cases, as such cases seem to have a lower relapse rate. In the present series, relapses were frequent; 57% of the patients had experienced a relapse within 5 yrs. We compared this with a group of MPA patients whose results we have reported previously [20] . Interestingly, the curves were very similar (Fig. 2) . The low number of PAN cases does, of course, introduce a great risk of a type one error. Other groups have shown lower relapse rates [25] , but in a small report from Australia with HBV-negative PAN patients, frequent relapses were also seen [13] .
Different prognostic factors have been used for systemic vasculitis. BVAS at diagnosis was higher in those patients who had the highest VDI at 1 and 5 yrs and in the patient who died. BVAS is a marker of vasculitic activity, and although the acute damage can be reversible, our findings indicate that it has a prognostic potential. Guillevin et al. [15] have shown FFS to be a prognostic factor for mortality in patients with PAN and Churg-Strauss Syndrome. The small size of our study prevents firm conclusion, but it is notable that the only patient who died had a FFS of zero. It is also difficult to draw prognostic conclusions on single factors, but we note that two out of three patients with malignant hypertension at diagnosis developed ESRD.
The incidence and prevalence figures vary between studies depending on the classification criteria used. From our data, we estimated an annual incidence of 1.6 per million in our part of Sweden. This is less than what many other authors have found, but it is probably due to our strict classification criteria. More recent reports from other countries have also shown a relatively low incidence [26] . In comparison, MPA, which is reported to have an annual incidence of 8.4-11.6 per million [26] , seems to be around five times more frequent.
In conclusion, our small series find PAN to be a rare but severe disease. Renal involvement with malignant hypertension and infarctions is common, and may lead to ESRD. Our data contradict the earlier opinion that PAN is a self-limiting disease with few relapses. We encourage others to publish case series to help revealing the true clinical picture of this old disease when applying the new definition. VDI is registered at 1 yr in 9 patients (I-IX) and for 7 patients also at 5 yrs. The score for each organ system and the total score for each patient is registered.
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Key messages
Polyarteritis nodosa is a rare but severe disease with a high incidence of renal involvement and frequent relapses. These patients must be followed carefully to prevent relapses and further organ damage.
